Zhang Financial LLC Sells 3,632 Shares of Stryker Corporation $SYK

Key Points

• Zhang Financial LLC trimmed its Stryker stake by 3.2% in the fourth quarter, selling 3,632 shares and ending with 110,348 shares valued at about $38.8 million.
• Several insiders also sold stock recently, including VP M. Kathryn Fink and Director Ronda E. Stryker, with insider selling totaling 318,720 shares worth about $99.3 million over the past three months.
• Stryker reported quarterly results that missed analyst estimates on both earnings and revenue, though the company also reaffirmed FY2026 EPS guidance and declared a quarterly dividend of $0.88 per share.

Zhang Financial LLC lowered its position in Stryker Corporation (NYSE:SYK - Free Report) by 3.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 110,348 shares of the medical technology company's stock after selling 3,632 shares during the period. Stryker makes up about 1.4% of Zhang Financial LLC's portfolio, making the stock its 16th largest position. Zhang Financial LLC's holdings in Stryker were worth $38,784,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker during the 4th quarter valued at $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker during the 3rd quarter valued at $27,000. Strive Asset Management LLC purchased a new stake in shares of Stryker during the 3rd quarter valued at $30,000. CGC Financial Services LLC purchased a new stake in shares of Stryker during the 4th quarter valued at $29,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in shares of Stryker during the 3rd quarter valued at $34,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Buying and Selling

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the firm's stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares of the company's stock, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 310,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company's stock, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 318,720 shares of company stock valued at $99,265,072 over the last three months. 4.60% of the stock is currently owned by insiders.

Stryker Stock Up 0.4%

SYK stock opened at $307.22 on Friday. The firm has a 50 day moving average of $322.61 and a 200 day moving average of $348.45. The stock has a market capitalization of $117.78 billion, a PE ratio of 35.56, a price-to-earnings-growth ratio of 1.93 and a beta of 0.80. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the business earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker's dividend payout ratio (DPR) is currently 40.74%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on SYK shares. BTIG Research decreased their price objective on Stryker from $397.00 to $379.00 and set a "buy" rating for the company in a report on Friday, May 1st. Needham & Company LLC lowered their target price on shares of Stryker from $454.00 to $418.00 and set a "buy" rating for the company in a research note on Friday, May 1st. Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research note on Friday, May 1st. Leerink Partners initiated coverage on shares of Stryker in a research note on Monday, April 13th. They issued an "outperform" rating and a $410.00 target price for the company. Finally, Wall Street Zen cut shares of Stryker from a "buy" rating to a "hold" rating in a research note on Saturday, May 16th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $395.48.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.